Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
Voltage-gated sodium channel alpha Nav1.5 (SCN5A) |
Target Info
|
Blocker |
[2] |
| References |
Top |
| REF 1 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
|
| REF 2 |
Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
